B7-H4 is Preferentially Expressed in Non-dividing Brain Tumor Cells and in a Subset of Brain Tumor Stem-like Cells

Overview

Journal J Neurooncol

Publisher Springer

Date 2008 May 15

PMID 18478183

Citations 35

Authors

Yu Yao

Xiaomei Wang

Kunlin Jin

Jianhong Zhu

Yin Wang

Sidong Xiong

Ying Mao

Liangfu Zhou

Affiliations

Soon will be listed here.

Abstract

B7-H4, a newly discovered member of B7 family that negatively regulates T cell-mediated immunity, may facilitate tumor progression by undermining host immunity. Recent studies show that brain tumor stem-like cells (TSCs) contribute to tumorigenesis. However, the relationship between B7-H4 and the clinical behavior of brain TSCs remains unclear. In this study, we found that B7-H4 was expressed in cultured tumor cells from human gliomas (n = 5) and medulloblastomas (n = 3). Double immunostaining indicated that B7-H4 was primarily restricted to non-dividing (Ki67(-)) cultured tumor cells. Tumor cells cultured under medium conditions favoring the growth of neural stem cells were able to form primary and secondary spheres, along with expression of neural stem/progenitor cell markers. These cells differentiated into different neural lineages when cultured in differentiation medium, indicating that these cells have TSCs characteristics. Double immunostaining showed that TSCs consisted of proliferative (Ki67(+)) and quiescent (Ki67(-)) cells. We also found that B7-H4 was expressed in a small population of CD133(+) cells sorted by flow cytometry. Interestingly, both CD133(+) and CD133(-) cells were tumorigenic in SCID mice in vivo. However, CD133(+) cells-initiated glioblastomas showed a higher proliferation index, compared to CD133(-) cells-induced glioblastomas in vivo. Secondary glioma cells derived from CD133(+) or CD133(-) cell xenografts expressed B7-H4 as well. Our data suggest B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subpopulation of brain TSCs, and CD133(-) tumor cells also have the capacity to initiate brain formation in vivo.

Citing Articles

Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.

Squalli Houssaini A, Lamrabet S, Nshizirungu J, Senhaji N, Sekal M, Karkouri M Vaccines (Basel). 2024; 12(6).

PMID: 38932383 PMC: 11209492. DOI: 10.3390/vaccines12060655.

Immune evasion in cell-based immunotherapy: unraveling challenges and novel strategies.

Li Y, Halladay T, Yang L J Biomed Sci. 2024; 31(1):5.

PMID: 38217016 PMC: 10785504. DOI: 10.1186/s12929-024-00998-8.

Cancer resistance to immunotherapy: What is the role of cancer stem cells?.

Gupta G, Merhej G, Saravanan S, Chen H Cancer Drug Resist. 2023; 5(4):981-994.

PMID: 36627890 PMC: 9771758. DOI: 10.20517/cdr.2022.19.

Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing.

Gisina A, Kholodenko I, Kim Y, Abakumov M, Lupatov A, Yarygin K Int J Mol Sci. 2022; 23(22).

PMID: 36430704 PMC: 9694247. DOI: 10.3390/ijms232214224.

Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy.

Taghavi B, Alizadeh N, Saeedi H, Ahangar N, Derakhshani A, Hajiasgharzadeh K Molecules. 2022; 27(11).

PMID: 35684481 PMC: 9182385. DOI: 10.3390/molecules27113545.

References

Walker P, Calzascia T, De Tribolet N, Dietrich P . T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev. 2003; 42(2):97-122. DOI: 10.1016/s0165-0173(03)00141-3. View

Sica G, Choi I, Zhu G, Tamada K, Wang S, Tamura H . B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity. 2003; 18(6):849-61. DOI: 10.1016/s1074-7613(03)00152-3. View

Hambek M, Werner C, Baghi M, Gstottner W, Knecht R . Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation. Eur J Cancer. 2007; 43(10):1502-7. DOI: 10.1016/j.ejca.2005.09.037. View

Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P . The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61(3):215-25; discussion 226-9. DOI: 10.1093/jnen/61.3.215. View

Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner P . CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67(9):4010-5. DOI: 10.1158/0008-5472.CAN-06-4180. View

Torp S . Diagnostic and prognostic role of Ki67 immunostaining in human astrocytomas using four different antibodies. Clin Neuropathol. 2002; 21(6):252-7. View

Salceda S, Tang T, Kmet M, Munteanu A, Ghosh M, Macina R . The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp Cell Res. 2005; 306(1):128-41. DOI: 10.1016/j.yexcr.2005.01.018. View

Pollack I, Hamilton R, Burnham J, Holmes E, Finkelstein S, Sposto R . Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery. 2002; 50(6):1238-44; discussion 1244-5. DOI: 10.1097/00006123-200206000-00011. View

Banes A, Shaw S, Tawfik A, Patel B, Ogbi S, Fulton D . Activation of the JAK/STAT pathway in vascular smooth muscle by serotonin. Am J Physiol Cell Physiol. 2004; 288(4):C805-12. DOI: 10.1152/ajpcell.00385.2004. View

10.

Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert A . B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006; 53(2):143-51. DOI: 10.1016/j.lungcan.2006.05.012. View

11.

Hemmati H, Nakano I, Lazareff J, Masterman-Smith M, Geschwind D, Bronner-Fraser M . Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A. 2003; 100(25):15178-83. PMC: 299944. DOI: 10.1073/pnas.2036535100. View

12.

Flies D, Chen L . The new B7s: playing a pivotal role in tumor immunity. J Immunother. 2007; 30(3):251-60. DOI: 10.1097/CJI.0b013e31802e085a. View

13.

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P . B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006; 203(4):871-81. PMC: 2118300. DOI: 10.1084/jem.20050930. View

14.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

15.

Prasad D, Richards S, Mai X, Dong C . B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity. 2003; 18(6):863-73. DOI: 10.1016/s1074-7613(03)00147-x. View

16.

Singh S, Clarke I, Terasaki M, Bonn V, Hawkins C, Squire J . Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-8. View

17.

Gerdes J, Lemke H, Baisch H, Wacker H, Schwab U, STEIN H . Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984; 133(4):1710-5. View

18.

Choi I, Zhu G, Sica G, Strome S, Cheville J, Lau J . Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family. J Immunol. 2003; 171(9):4650-4. DOI: 10.4049/jimmunol.171.9.4650. View

19.

Jedema I, Barge R, Nijmeijer B, Willemze R, Falkenburg J . Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin. Leukemia. 2003; 17(10):2049-51. DOI: 10.1038/sj.leu.2403085. View

20.

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View